Abstract Rademikibart (CBP-201) is a next-generation human monoclonal antibody
targeting IL-4Rα, undergoing evaluation in Phase 2 clinical trials for the treatment of …

Abstract IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic
dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human …

Dupilumab is a fully human monoclonal antibody directed against the interleukin (IL)‐4
receptor α subunit (IL‐4Rα) of IL‐4 heterodimeric type I and type II receptors that mediate IL …

Abstract Development of antagonistic antibody (Ab) against interleukin-4 receptor alpha (IL-
4Rα) subunit of IL-4/IL-13 receptors is a promising therapeutic strategy for T helper 2 (TH2) …

Background Dupilumab, a fully human monoclonal antibody that binds IL‐4Rα and inhibits
signaling of both IL‐4 and IL‐13, has shown efficacy across multiple diseases with …

Dupilumab, an IL-4/IL-13 receptor blocker, has been linked to emergent seronegative
inflammatory arthritis and psoriasis that form part of the spondyloarthropathy spectrum. We …

Type 2 immune response refers to a complicated series of immune responses characterized
by Th2 polarization and Th2 cytokines secretion. The IgE secretion, airway hypersensitivity …

Dupilumab is a fully humanized monoclonal antibody, capable of inhibiting intracellular
signaling of both interleukin (IL)-4 and IL-13. These are two molecules that, together with …

Interleukin (IL)-6 is a typical cytokine featuring redundancy and pleiotropic activity. It
contributes to host defense against pathogens, but dysregulation of IL-6 production plays a …

Background Inhibition of interleukin (IL)-13, a Type 2 inflammatory mediator in asthma,
improves lung function and reduces exacerbations; however, more effective therapies are …